An Open Label Trial of Dianhydrogalactitol (VAL-083) and Radiation Therapy in Treatment of Newly Diagnosed GBM Patients With An Unmethylated Promoter of the Methylguanine-DNA Methyltransferase (MGMT) Gene
Phase of Trial: Phase II
Latest Information Update: 13 Sep 2017
At a glance
- Drugs Dianhydrogalactitol (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Del Mar Pharmaceuticals
- 08 Sep 2017 Planned initiation date changed from 1 Oct 2017 to 30 Sep 2017.
- 08 Sep 2017 Status changed from not yet recruiting to recruiting.
- 06 Sep 2017 According to a DelMar Pharmaceuticals media release, update from the study will be presented at the 19th Annual Rodman & Renshaw Global Investment Conference 2017.